Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady Purchases 250,000 Shares

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) CEO Todd Brady acquired 250,000 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average cost of $1.67 per share, for a total transaction of $417,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at $2,874,567.66. This represents a 16.99% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Aldeyra Therapeutics Stock Performance

Shares of ALDX opened at $1.63 on Friday. The company’s 50 day moving average price is $1.68 and its 200 day moving average price is $3.68. Aldeyra Therapeutics, Inc. has a 52 week low of $1.07 and a 52 week high of $6.18. The company has a market capitalization of $98.32 million, a PE ratio of -3.54 and a beta of 1.19.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. On average, equities analysts forecast that Aldeyra Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALDX has been the subject of several recent research reports. HC Wainwright reissued a “neutral” rating and issued a $2.00 target price (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. Wall Street Zen raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. Finally, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.50.

Institutional Trading of Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC lifted its stake in shares of Aldeyra Therapeutics by 146.6% in the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock worth $1,459,000 after buying an additional 513,187 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Aldeyra Therapeutics by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock worth $1,055,000 after buying an additional 11,912 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Aldeyra Therapeutics by 18.1% in the first quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock worth $231,000 after buying an additional 20,980 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $33,000. Finally, Abel Hall LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $26,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.